Articles by Brian O'Connell - BioPharm International



Articles by Brian O'Connell

Life Sciences and Socially Responsible Investing

Although loaded with contradictions, biopharmaceutical-based socially responsible investing is picking up pace in the market
Dec 1, 2007

More than $1 out of every $9 under professional management in the United States is involved in socially responsible investing.

Venture Funding Returns to Life Sciences

The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008
Nov 1, 2007

The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008

Street Talk: Summer No Picnic for Investors

At a time when liquidity is difficult to come by, biopharmaceutical firms will find it difficult to find the capital they need to keep going
Sep 1, 2007

Closer examination shows there's a strong bond between the biotech market and the unraveling credit markets.

Street Talk: Small-Cap Biopharmaceutical Stocks

While small caps are more volatile than their large-cap brethren, they offer benefits galore to investors of all stripes
Aug 1, 2007

When you start out, keep your small-cap exposure to no more than 10% of your holdings, and gradually increase.

Street Talk: Cautious Optimism: the Watchwords for Volatile Sector

Biotech doesn't play by the same rules that most industries do when it comes to stock performance
Jul 1, 2007

We're seeing an uptick in biotech investing from the venture capital community, a good sign that biotech can rise even higher than the broader markets.

Street Talk: Looking for a Safe Haven in US Stock Market? Rx Might be Healthcare

Strong valuations, impressive new drug development pipelines, and solid balance sheets project a major long-term buying opportunity in healthcare
Apr 1, 2007

Investors should also scour the landscape and think creatively when investing in healthcare this year.

Street Talk: CEO Paychecks: How They Are Determined

A "pay-for-hay" performance culture is embedded in the industry's DNA.
Feb 1, 2007

In the September 2006 issue I wrote about the ticklish issue of CEO pay and how shareholder groups, especially the powerful pension and other institutional groups, are growing sick and tired of CEO overpayment and underperformance.

Street Talk: Biopharm Exchange-Traded Funds: Their Time has Come

Biopharm ETFs are popping up everywhere, offering investors the opportunity to climb on the backs of companies fighting disease
Jan 1, 2007

On a recent plane ride from Phoenix to Philly, I was leafing through a copy of the San Francisco Business Journal. I was taken aback by a story on the emerging trend of biopharm exchange-traded funds (ETFs), and how much of an impact they're having on Wall Street and on investors.

Street Talk: Stem Cells: Tough Sell on Wall Street?

Adult stem cells are operating under the radar a bit, but are way ahead of their embryonic offshoots in effective products on the market.
Dec 1, 2006

There are 72 maladies for which human patients have received some benefit from adult stem cell interventions.



Click here